On September 30, 2022, the President signed the FDA User Fee Reauthorization Act of 2022, renewing the U.S. Food and Drug Administration’s authority to collect user fees that help fund the review of drugs, biologics, and related products. Within that broader law, the FDA describes a biosimilar-specific framework referred to as BsUFA IV, which the agency’s public materials associate with fiscal years reaching to 2028.
Because the available evidence is thin and comes primarily from the FDA’s own documentation, any assessment of how likely BsUFA IV is to be “formally confirmed” in the coming week must start with a narrow question: what, exactly, has already been enacted, and what remains contingent.
What the FDA Says About BsUFA IV and FY 2028
In materials published on FDA.gov describing the Biosimilar User Fee Act (BsUFA) program, the agency refers to the current iteration as “BsUFA IV” and associates it with fiscal years that extend through 2028. This is the core, primary-source basis for linking BsUFA IV to the 2028 time frame.
Those FDA materials indicate that BsUFA IV is part of the broader FDA user fee framework reauthorized in 2022. In other words, Congress and the President have already acted to continue the biosimilar user fee program under this fourth iteration. The FDA’s public description of BsUFA IV, including its stated fiscal-year span, therefore reflects the agency’s understanding of how the enacted law and negotiated commitments apply over time.
From this, two points are grounded in the available evidence:
- BsUFA IV exists as a defined program within the FDA’s user fee structure, as described by the agency itself on FDA.gov.
- The FDA associates BsUFA IV with fiscal years extending to 2028, again based on its own public-facing documentation.
What the evidence does not clearly show is any separate, impending decision point in “the next week” that would newly “confirm” BsUFA IV for fiscal year 2028. The FDA’s description reads as a standing framework rather than a week-specific event.
How Much Has Already Been Decided?
The signing of the FDA User Fee Reauthorization Act of 2022 established the legal authority for the FDA to collect biosimilar user fees under BsUFA IV. That act is already law; there is no indication in the FDA’s own materials that the basic existence of BsUFA IV, or its multi‑year scope, is still pending.
Based on the FDA’s description:
- Legal authority: The statutory authority to run the biosimilar user fee program under BsUFA IV is already in place as part of the 2022 reauthorization.
- Program framing: The FDA’s reference to fiscal years up to 2028 suggests that, from the agency’s perspective, BsUFA IV is designed as a multi‑year framework.
Where the uncertainty lies is not in whether BsUFA IV exists, but in how fully each fiscal year’s operational details—such as fee levels, performance goals, and implementation steps—are locked in versus subject to routine updates or adjustments.
Because the only direct evidence available is the high‑level FDA description, it is not possible to say, based solely on that record, whether any additional, discrete “formal confirmation” step specific to FY 2028 is scheduled or required in the very near term.
Why Independent Corroboration Matters
The current evidence set is limited to FDA.gov as a primary source. Independent corroboration—such as detailed legislative summaries, budget documents, or external analyses—has not been presented in the material available here.
That matters for two reasons:
- Interpreting timelines: The FDA’s reference to fiscal years through 2028 shows intent and planning horizon, but without corroborating documents it is harder to distinguish between what is fully fixed in statute and what could be adjusted administratively or through future appropriations.
- Assessing near‑term events: The reader’s question centers on whether BsUFA IV for FY 2028 is likely to be “formally confirmed” in the next week. With only the FDA’s broad program description in hand, there is no direct evidence of a scheduled decision, vote, or announcement tied specifically to that week.
The claim that “independent corroboration is limited in this cycle and should be monitored as additional reporting arrives” is consistent with the evidence constraints here. It is a reminder that, at this stage, analysis must stay close to what the FDA itself has put on the record.
Implications for Patients, Providers, and Manufacturers
Even within this narrow evidentiary frame, some consequences of BsUFA IV’s multi‑year structure can be reasonably inferred, with the caveat that these inferences rest on how user fee programs typically function and on the FDA’s own description of BsUFA IV’s time span.
For patients and providers: A multi‑year biosimilar user fee framework generally supports continuity in the FDA’s review capacity. If BsUFA IV is structured to run through 2028 as the FDA indicates, that continuity can help sustain predictable timelines for biosimilar application review, which in turn affects how quickly new biosimilar options can reach the market. The evidence from FDA.gov supports the existence of such a multi‑year framework; it does not, however, quantify its impact on review times or access.
For manufacturers: User fee programs provide a degree of planning certainty for companies preparing biosimilar applications. Knowing that BsUFA IV is mapped out through 2028, as the FDA’s materials suggest, allows firms to anticipate the fee environment and regulatory engagement structure over several fiscal years. Again, this is an inference from the stated fiscal span of BsUFA IV, not a quantified outcome.
For the FDA itself: A defined BsUFA IV horizon through 2028 implies a stable funding and performance‑goal framework over that period, subject to the details of how Congress and the agency implement the law year by year. The FDA’s own description is the basis for this conclusion; without additional documents, the specific resource levels and performance targets remain outside the available evidence.
How Likely Is “Formal Confirmation” in the Next Week?
Given the constraints of the record, the most defensible answer is carefully bounded:
- The existence of BsUFA IV and its association with fiscal years reaching to 2028 are already reflected in FDA.gov materials and derive from a law signed in 2022.
- There is no direct evidence in the available FDA documentation of a separate, imminent decision point in the next week that would newly “confirm” BsUFA IV for FY 2028.
Because there is no documented, week‑specific trigger in the evidence provided, assigning a probability to “formal confirmation in the next week” would go beyond what the record supports. The most that can be said, grounded in the FDA’s own description, is that BsUFA IV is already treated by the agency as a multi‑year framework extending to 2028, rather than as a program awaiting near‑term confirmation.
What to Watch Next
With independent corroboration still limited, the most relevant developments to monitor are:
- Further FDA documentation: Additional guidance, performance‑goal letters, or implementation updates on FDA.gov that clarify how BsUFA IV is applied year by year up to 2028.
- Congressional or budget actions: Any public documents that link annual appropriations or related measures to BsUFA IV’s operation in later fiscal years, including 2028.
- Stakeholder communications: Statements from biosimilar manufacturers or professional associations that reference BsUFA IV’s time horizon and how they are planning around it.
Until such materials are available and independently corroborated, the safest evidence‑based position is that BsUFA IV is already structured by the FDA as a multi‑year biosimilar user fee program extending through 2028, and that there is no clear, documented indication of a separate, high‑stakes confirmation event specifically scheduled for the coming week.
